Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 19/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21445237 | 1.00 | FPR2 (0.78) | FPR2MEN1KMT2A | |
| SCHEMBL23039409 | 0.89 | FPR2 (0.86) | FPR2MEN1KMT2A | |
| SCHEMBL21445202 | 0.88 | FPR2 (1.00) | FPR2MEN1KMT2A | |
| SCHEMBL30057046 | 0.87 | FPR2 (0.68) | FPR2MEN1KMT2A | |
| SCHEMBL26000676 | 0.87 | FPR2 (0.68) | FPR2MEN1KMT2A | |
| SCHEMBL21445204 | 0.84 | FPR2 (0.85) | FPR2MEN1KMT2A | |
| SCHEMBL21445231 | 0.84 | FPR2 (0.75) | FPR2MEN1KMT2A | |
| SCHEMBL26002224 | 0.83 | FPR2 (0.76) | FPR2MEN1KMT2A | |
| SCHEMBL23039437 | 0.83 | FPR2 (0.72) | FPR2 | |
| SCHEMBL21445215 | 0.83 | FPR2 (0.72) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034193-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2025-01-30 | — | — | US | disclosed |
| US-12145963-B2 | Phenothiazine derivatives and uses thereof | CAMP4 THERAPEUTICS CORPORATION (US) | 2024-11-19 | — | — | US | disclosed |
| US-20230257410-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-11542290-B2 | Phenothiazine derivatives and uses thereof | CAMP4 THERAPEUTICS CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257410-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | RPLP2, RPS2, RPLP1 | FPR2 2716/4885MEN1 1826/4885KMT2A 1086/4885 |
| US-12145963-B2 | Phenothiazine derivatives and uses thereof | RPLP2, RPS2, RPLP1 | FPR2 2716/4885MEN1 1826/4885KMT2A 1086/4885 |
| US-20250034193-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | RPLP2, RPS2, RPLP1 | FPR2 2716/4885MEN1 1826/4885KMT2A 1086/4885 |
| US-11542290-B2 | Phenothiazine derivatives and uses thereof | RPLP2, RPS2, RPLP1 | FPR2 2716/4885MEN1 1826/4885KMT2A 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.